Lb Pharmaceuticals (LBRX) Cash & Equivalents (2024 - 2026)

Lb Pharmaceuticals' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $320.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents changed N/A year-over-year to $320.7 million; the TTM figure through Mar 2026 stood at $320.7 million (changed N/A YoY), while the FY2025 annual figure was $250.2 million, up 988.75% from the prior year.
• Cash & Equivalents was $320.7 million for Q1 2026 at Lb Pharmaceuticals, up from $250.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $320.7 million in Q1 2026 to a low of $23.0 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $215.9 million across 3 years, with a median of $260.0 million in 2025.
• Biggest YoY gain for Cash & Equivalents was 988.75% in 2025; the steepest drop was 988.75% in 2025.
• A 3-year view of Cash & Equivalents shows it stood at $23.0 million in 2024, then jumped by 988.75% to $250.2 million in 2025, then rose by 28.18% to $320.7 million in 2026.
• The last three Cash & Equivalents figures came in at $320.7 million (Q1 2026), $250.2 million (Q4 2025), and $269.7 million (Q3 2025), per Business Quant data.